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Aversion to pain and attraction to reward are strong motivators of behavior across 
species [12]. The rewarding nature of pain relief [56] suggests that stimuli or contexts of 
opposing valence may in fact lie along a continuum [51] but the neural circuits 
responsible for this reciprocal processing are poorly understood [16]. Consistent with 
this theory reward may conversely impart analgesia. It is believed that the calming effect 
of giving sugar (sucrose in solution) to human infants is a direct example of the 
phenomenon of pain reduction by reward [59] and it is empirically applied in paediatrics 
[36]. A recent systematic review concluded that sucrose may offer a reduction in 
procedural pain in new born infants [68]; however, there is limited evidence of a direct 
modulation of nociceptive processing at either the spinal or cortical level [66]. Thus the 
role of sucrose as a bona fide analgesic in human infants remains in question until more 
is known about the underlying neurobiology [28]. 
 
A sucrose-analgesia phenomenon has also been demonstrated in neonatal rats [14], 
which at least in part, survives mid-collicular decerebration [6], can be reversed by an 
opioid receptor antagonist [14], and reduces Fos-like immunoreactivity in the spinal cord 
[61] suggesting the involvement of endogenous descending inhibitory opioidergic 
signalling. In adults sucrose remains a strong motivator to feed, even in potentially 
hazardous circumstances [30]. However, the relative contributions of descending 
inhibition of nociceptive input versus more cognitively driven analgesia remains 







































































We have developed a simple and reliable model of sucrose drinking-induced analgesia 
in adult Sprague-Dawley rats using the Hargreaves’  test of hind paw thermal sensitivity 
as a nociceptive assay. We used this assay to characterise the analgesic phenomenon 
and the context in which it appears. Specifically, we compared previous findings in 
neonatal animals [5, 15, 61],  by examining the potential role of endogenous analgesia 
mediated by opioid and catecholaminergic neurotransmitters at the spinal level via 
descending inhibition. We further tested the requirement of expectation and learned 
experience [26] by the substitution of sucrose for water in hypovolaemic and euvolaemic 
animals. Finally, to examine the requirement for appetitive motivation in the analgesic 
effect of sucrose as a reward [31] we compared the effect of voluntary sucrose drinking 
with passive administration via an intraoral cannula.
 
Our results reveal an acute, potent and robust inhibitory effect of sucrose drinking on 
thermal nociceptive behavior. Unlike sucrose-analgesia in neonates the phenomenon is 
independent of endogenous opioid signalling and does not operate via classical 
descending catecholaminergic inhibition of the spinal cord circuitry. Experience of 
sucrose drinking had a conditioning effect sufficient to elicit a short-lasting placebo-like 
analgesia by water drinking alone in euvolaemic animals. In chronically cannulated 
animals sugar analgesia only appeared after repeated conditioning by oral perfusion, 
and was completely prevented systemic dosing with the cannabinoid CB1 receptor 








































































All experiments and procedures were approved by the Institutional Animal Care and 
Use Committee at Seoul National University (SNU-151113-2) and are reported here in 
accordance with the ARRIVE guidelines [48]. Male and female Sprague-Dawley rats 
were purchased from Orient Bio (Charles River, Korea) aged 5 weeks and habituated 
for one week prior to experiments. Animals were maintained in an air conditioned clean 
facility (22 ± 2°C, 50 ± 10% humidity) and provided standard lab chow and water ad 
libitum, except when food or water was removed for deprivation experiments for the 
duration indicated. Behavioral testing was performed between the hours of 09.00-17.00. 
At the end of experiments animals were killed by rising concentration of CO2 in 
accordance with Schedule 1 of the UK Home Office Animals (Scientific Procedures) Act 
1986. 
 
Thermal withdrawal latency testing (Hargreaves’ test) 
Hind paw thermal withdrawal latencies were tested using a thermal plantar analgesia 
instrument (Ugo Basile, Italy). After habituation on the glass plate, when rats were 
resting but not sleeping, the infrared stimulator (50% intensity) was applied to the 
middle area of hind paw. Thermal stimuli applied during voluntary drinking were started 
1-2 s after the commencement of imbibing. A positive response was determined by a 




































































times on each paw with an interval of at least 2 min and the time taken to withdraw was 
averaged per paw, per rat. A cut-off time was set at 20 s to prevent tissue damage. For 
examination of spinal c-fos immunoreactivity after Hargreaves’ testing a manually 
controlled thermal stimulator was used (Plantar Analgesia Meter, IITC Life Science, 
USA) to deliver repetitive stimuli of 10 s duration. 
 
Drinking task training 
Training was performed daily, typically between the hours of 09.00 and 13.00. Rats 
were habituated in individual test cages (30 – 60 min) on an absorbent mat which was 
removed prior to testing. Animals were provided with 10-20 ml of either a sucrose 
solution (10% in water) or sucralose (0.017% in water) in a plastic tray with access via 
an aperture (40 mm diameter) in the cage via a removable door (Figure 1A). At the 
commencement of drinking, a period of 30 s access was allowed before the door was 
closed. After a refractory period of 5 – 10 mins rats were allowed three more access 
periods (four trials in total). Training was deemed complete when animals spent more 
than 10 s drinking during any given 30 s access period (typically within 5 sessions). 
 
Local inflammation model 
Under brief isoflurane anaesthesia, rats received an intraplantar injection of complete 
Freund’s adjuvant (CFA, 50 µg) in one paw (left or right). CFA was prepared as a 2:1 
emulsion in sterile saline. Rats received a subcutaneous injection of CFA as a 75 µl 








































































Cannula were implanted using a variation on previous methods [34, 38]. For acute 
cannulation [34], under isoflurane anesthesia, a curved 20G needle and 32 mm catheter 
(3S Cath, Dukwoo Medical) was inserted intraorally through the buccal mucosa just 
rostral to the lower first molar on the right side. The needle and catheter was passed 
subcutaneously over the masseter muscle and between the right eye and ear to emerge 
on the back of the head between the ears. The needle was then removed and 20 cm of 
PE10 tubing (16 µl dead space volume) was passed through the catheter, which was 
then also removed leaving the tubing in place. A 3-4mm length of PE50 tube was 
fashioned into a flanged end and fitted to the oral end of the tubing via cyanoacrylate 
glue. The flanged end was pulled into the mouth to rest flush on the inner cheek. The 
protruding end was secured with a silk suture to the back of the head. Rats were 
recovered for at least one hour after cannulation before testing.  
 
For chronic cannulation [38] in sucrose trained animals, an 18-gauge syringe needle 
was inserted between the scapulae and passed subcutaneously towards the intra-oral 
site (buccal mucosa just rostral to the lower first molar on the right side). An intra-oral 
catheter made of PE90 tubing with one end heat-flared to form a 2 mm-diameter flange 
was inserted from the intra-oral site and externalized between the shoulders. The 




































































and glued with silastic medical adhesive silicone (Dow Corning) to fix the PE90 tubing. 
Rats were recovered for 5 days prior to oral perfusion experiments. 
 
Intra-oral perfusion 
Cannulated animals were placed in the testing chamber for 30 mins to habituate. The 
open end of cannula tubing was fixed to the top of the cage and fitted to an automatic 
syringe pump via a 40 cm length of PE50 tubing and 25G needle. 5 ml syringes and 
tubing were pre-loaded with water, sucrose (10%) solution or air (sham). In all perfusion 
experiments thermal stimulation began 10 s after the start of oral perfusion as indicated 
by masticatory movement of the rat jaw in the case of water and sucrose solution.  Each 
paw was tested twice and average latencies plotted per animal. A 20 s flush with water 
was performed to remove traces of the previous solution between each trial. For 
repetitive sucrose experience in chronically cannulated rats, all animals were given a 
delivery of water, sucrose (10%) solution, or air (sham) in a random order, repeated 5 
times in daily sessions for 5 consecutive days  
 
Intrathecal (lumbar spinal cord) cannulation 
Intrathecal cannulation was performed in accordance with previously published methods 
[39]. All surgical tools, solutions and catheter materials were sterilized beforehand by 
autoclave or ethylene oxide (EO) gas, respectively. Animals were weighed and given a 
prophylactic dose of the antibiotic enrofloxacin (5mg/kg) subcutaneously prior to 
surgery. Under isoflurane anaesthesia the lower lumbar and mid-scapulae areas of the 




































































2cm long) and a 24 gauge catheter needle was inserted at a 45 degree angle between 
the 5th and 6th lumbar vertebrae. Correct placement of the needle into the vertebral 
canal is indicated by a slight twitch of the tail [54]. A 32 gauge intrathecal cannula with 
stylet (ReCathCo) was inserted into the intrathecal space by slowly advancing the 
cannula rostrally (6 cm). The catheter stylet was then removed and the cannula 
attached to length of PE10 tubing (10 cm) by cyanoacrylate glue and attached to the 
muscle fascia with 7-0 silk. The lumbar incision was closed with 2-3 skin clips. The 
PE10 tubing was passed under the back skin and exited the incision between the 
scapulae. Here the tubing was connected to a back-mounted pedestal system (with 6 
mm side connector) (Plastics One) via a short length (1.5 cm) of thick-walled PE50 
tubing, again fixed with cyanoacrylate glue. The pedestal mesh was attached to the 
underlying muscle fascia with 6-0 sutures and the wound around the pedestal closed 
with 4-0 silk sutures. The cannula system was filled with 20 µl of sterile saline to 
maintain patency during recovery (3-4 days). Incision sites were treated with iodine and 
rats were returned to warmed individual cages for recovery. Successful cannula 
placement was confirmed after experiments by reversible bilateral hind-limb paralysis 
after intrathecal administration of 2% lidocaine (20 µl), and cresyl violet dye (20 µl) 
labelling of lumbar spinal cord at post-mortem. Out of 12 sucrose-trained animals that 
underwent intrathecal catheterization, patency was maintained in seven animals which 






































































Drug or vehicle-only solutions were back-loaded into a loading cannula connected to a 
50 µl Hamilton syringe (with 23G needle) on an automatic syringe pump (KD Science). 
Drugs or vehicle solutions were delivered as a 10 µl bolus followed by 18.6 µl flush with 
sterile saline given at 10 µl/min. After injection the connector was removed and the back 
pedestal cannula was fitted with a dust-cap. Animals were then immediately returned to 
the testing cage for thermal sensory testing. 
 
Drug treatments 
Naloxone HCl (Sigma) was prepared as a stock (50 mg/ml) in distilled water and diluted 
in 0.9% saline vehicle before systemic (1 mg/kg, i.p.) [26, 53] or spinal (10 µg, i.t.) [69] 
administration. Yohimbine HCl (Tocris) was prepared as a stock (10 mg/ml) in DMSO 
and diluted in 0.9 saline (30% DMSO vehicle) for spinal (30 µg, i.t.) [39] administration. 
S-sulpiride HCl (Sigma) was prepared as a stock (30 mg/ml) in DMSO and diluted in 
saline (10% DMSO vehicle) for systemic (10 mg/kg, i.p.) [9] administration. The CB1 
receptor antagonist, rimonabant (SR141716A) (Tocris) was prepared as a stock in 
DMSO and diluted in a vehicle containing 2% tween-80 and 20% DMSO in 0.9% saline 
45] for systemic administration (5 mg/kg, i.p.) [37, 73]. Sensory testing was performed 
10-15 mins after systemic and spinal injections and completed within 45 min of drug 
treatment. The same animals underwent alternative treatment of drug or vehicle 
solutions separated by at least one rest day. Spinal drug treatments were followed by a 





































































Spinal c-fos assessment 
Sucrose-trained male SD rats received thermal stimulation (IITC Life Sciences, Plantar 
test) to their right hind paw of a set duration (10 s) repeated 15 times at an interval of 1-
2 mins, either during sucrose drinking (n=6) or while resting (control, n=6). 2 h after the 
final heat stimulation animals received a lethal dose of sodium pentobarbital (>60 
mg/kg, i.p.) and were transcardially perfused sequentially with PBS (0.01 M) followed by 
paraformaldehyde (4% in PBS). c-fos immuno-labelling was performed according to 
previously published methods [8]. The lumbar spinal cord was removed for post-fixation 
overnight and cryopreserved in 30% sucrose for 3-4 weeks at 4°C. Spinal tissue blocks 
were embedded in OCT compound (Leica) and free-floating spinal cord sections (50 
µm) were cut on a cryostat followed by immunolabelling with an anti-c-fos (Ab-5) (4-17) 
rabbit polyclonal antibody (1:10,000, Calbiochem) and visualised using DAB staining 
technique (Vector Laboratories) before mounting on gelatin-coated glass slides. Images 
were acquired on a light microscope and analysed for the number of c-fos-like 
immunoreactive nuclei per section (four sections per animal) using the “analyse 
particles” function on ImageJ (NIH). Image thresholding prior to particle analysis was 
performed by an experimenter blinded to the treatment group. Two out of 12 animals 
(one sucrose, one control) were removed from analysis due to poor tissue fixation. 
 
Statistics 
Comparisons before and after sucrose drinking were made with paired t test. 
Comparisons between three or more groups of time points were made with repeat 




































































Two-way ANOVA was used for comparison of the effect of drug treatment on thermal 
withdrawal latencies before and during sucrose drinking. All tests are two-sided. 
Behavioral data were obtained by an observer blind to the treatment group. Analyses 
were performed using GraphPad Prism version 5.00 for Windows, GraphPad Software, 
San Diego California USA, www.graphpad.com. Data are presented as mean ± 









































































In an initial study we fasted 6-8 week old rats by removing access to chow overnight 
(12-16 h) and placed them in a testing apparatus with access to a sucrose solution via a 
closable aperture (Figure 1A, B). Thermal withdrawal latencies were not different after 
the transient fasting compared to the pre-fasting control. Subsequent consumption of a 
solution of 10% sucrose in water (equivalent to the typical sugar content found in soft 
drinks and fruit juices [75]) increased the thermal withdrawal latency from 10.9 ± 0.8 s to 
14.8 ± 0.6 s (p<0.001, repeat measures One-way ANOVA, n=6 rats) (Figure 1C). 
 
To mitigate the confounds of fasting in rats, such as metabolic stress and polyuria 
causing dehydration [55], we adopted a training schedule of sucrose drinking (see 
Methods). Prior to training, non-fasted animals displayed a long and variable latency to 
drink, taking an average of 72 ± 23 s (n=12) once given access to the sucrose solution. 
After several days of training, however, rats readily drank the sucrose solution upon 
access, with the average time taken to drink significantly reduced to less than 2 s by the 
sixth training session (Figure 2A). Trained rats consistently displayed an increase in 
withdrawal latency while drinking sucrose (10.7 ± 0.5 s) compared to resting baseline 
(8.6 ± 0.3 s, p=0.0002, paired t test, n=12 rats) (Figure 2B). Rats were often observed to 
continue consuming sucrose after withdrawal of the hind paw from the thermal stimulus, 
at which point the access window was closed. The sucrose effect was transient and the 
withdrawal latency returned to baseline when tested 1-2 min later. We also found the 
same phenomenon in female rats, showing that they were also capable of being trained 




































































by the fifth training session (n=12 rats, Repeat measures One-way ANOVA: F(4, 
44)=5.175, p=0.0017. Dunnett’s post -test: Session 1 vs 5, t=3.806, **p<0.01), and paw 
withdrawals increasing from 10.3 ± 0.3 s at rest to 12.6 ±  0.3 s during sucrose drinking 
(n=12 rats, paired t test: t=8.919, p<0.0001)
 
In a subsequent session, male sucrose-trained rats were given access to the drinking 
area but not provided with any solution. In this experiment animals showed the same 
movement to the window, inserting their head through the aperture, but displayed no 
consistent change to their withdrawal latency (p=0.1247, paired t-test, t=1.662; n=12 
rats) compared to rest (Figure 2C), suggesting that contextual expectancy alone is not 
sufficient for the analgesic response to a sweet reward. In a separate experiment rats 
were trained to consume the non-nutritive sweetener sucralose (0.017% w/v in water) at 
a concentration equivalent to the sweetness of 10% sucrose (1:600) [76]. Withdrawal 
latencies recorded during sucralose drinking were also elevated (11.1 ± 0.7 s; 
p=0.0162, n=12 rats, paired t-test) compared to prior resting values (9.3 ± 0.5 s) (Figure 
2D). There was no difference in the percentage change in withdrawal latency during 
sucrose (125 ± 4% of resting) or sucralose drinking (120 ± 7% of resting) (p=0.5676, 
unpaired t-test, t=2.074; n=12 rats per group).  These results indicate that sweet 
substances do not need calorific value to produce analgesia.  
 
Next we asked whether sucrose-drinking analgesia persisted in rats in an already 
sensitised state. At baseline, prior to sensitisation with the inflammatory reagent 




































































sucrose drinking (Figures 3A and 3B). A single bolus of CFA (50 µg) given 
subcutaneously to the plantar surface of the hind paw resulted, 24 h later, in a 
significant reduction in withdrawal latency in the injected (ipsilateral) paw, indicative of 
inflammatory hyperalgesia (Figure 3A).  After CFA treatment, subsequent drinking of 
sucrose solution still produced an increase in withdrawal latency by an equivalent 
degree to that seen before sensitisation (Figure 3A), suggesting a potent analgesic 
mechanism capable of partially reversing inflammatory hypersensitivity. The effect of 
sucrose on the withdrawal latency in the untreated contralateral paw was also 
preserved, albeit at a slightly reduced magnitude (though not significantly) at Day 2 
compared to Day 0 (Figure 3B), likely due to the increased weight-bearing on the 
uninflamed paw. These results complement previous findings in neonates [61] and 
suggest that the sucrose analgesia phenomenon in adults is sufficient to attenuate 
responses from hypersensitive thermal afferents. 
 
Sucrose-analgesia in neonates has been shown to be an opioid receptor-dependent 
phenomenon [5, 14]. However, pre-treatment with the opioid receptor antagonist 
naloxone at a dose shown to block both endogenous and exogenous opioid analgesia 
in rats (1 mg/kg, i.p.) [26, 53] (Figure 4A) or given directly to the spinal cord (10 µg, i.t.) 
[69] (Figure 4B), did not block the analgesia induced by sucrose drinking. 
 
Dopaminergic and noradrenergic neurotransmitter systems are involved in directing 
behavior towards sweet reward [17, 62] and are both capable of mediating analgesia via 




































































release of dopamine in the striatum, a critical component of the brain’s reward system 
and a driver of hedonic behavior even in the face of unpleasant stimuli [71]. In the spinal 
cord dopamine produces thermal analgesia via D2-like receptors [43, 70], therefore we 
treated rats systemically with the D2-like receptor antagonist sulpiride at 10 mg/kg, a 
dose sufficient to prevent analgesia induced by spinal administration of the 
dopaminergic agonist apomorphine [9]. The dopamine receptor antagonist did not alter 
sucrose analgesia (Figure 4C).  
 
The actions of noradrenaline on α2-adrenoceptors to inhibit spinal nociception are well 
characterised [57, 67]. Sweet reward also increases the activity of noradrenergic locus 
coeruleus (LC) neurons, helping to direct attention to reward by releasing noradrenaline 
in the prefrontal cortex [17]. Conversely chemical ablation of LC projections dramatically 
reduces voluntary sucrose intake [4]. LC neurons are also among the brainstem nuclei 
to have been implicated in the phenomenon of sucrose analgesia in neonates [6, 49]. 
As systemic administration of α2 antagonists can have confounding autonomic and 
sedating side effects, we targeted the spinal cord directly with intrathecal injection of 30 
µg yohimbine, a dose sufficient to block endogenous noradrenergic spinal analgesia 
[39]. However, intrathecal yohimbine also had no effect upon sucrose analgesia (Figure 
4D). Together these results suggest that these descending catecholaminergic pathways 
are unlikely to be involved in the analgesic response to sucrose. 
 
To examine whether sucrose drinking is inhibiting nociception at the spinal level (by 




































































measure of activity in nociceptive circuits [40]. Animals received repetitive thermal 
stimulation to one hind paw either at rest or during concurrent sessions of sucrose 
drinking. Spinal cords were fixed 2 h after the final stimulation and processed for c-fos-
like immuno-reactivity. The pattern of c-fos-like immunolabelling in the medial region of 
the superficial dorsal horn of the lumbar spinal cord with the repetitive stimulation 
protocol (10 s thermal stimulation repeated once per minute for 15 minutes) was 
consistent with previous observations of hind paw thermal stimulation [18, 77] and 
confirmed activation of the spinal nociceptive circuity (Figures 5A and B, Control). We 
also observed a small number of positive nuclei in the neck region of the deep dorsal 
horn, corresponding to laminae V-VI of the spinal cord. No c-fos-like reactivity could be 
discerned in the contralateral dorsal horn or ipsilateral ventral horn. Animals which 
drank sucrose during each thermal stimulation also showed similar pattern of c-fos 
expression in the spinal cord (Figure 5A), and quantification of c-fos-like immuno-
reactivity showed no difference between groups in either superficial or deeper laminae 
of the spinal dorsal horn (Figure 5B). This result suggests that sucrose drinking does 
not significantly alter the activity in nociceptive circuits at a spinal level. 
 
Next, we asked whether sweet taste was required for the analgesic effect by providing 
motivation to drink water instead of a sucrose solution. Rats deprived of water for 24 h 
readily drank water upon its presentation and this also produced an increase in 
withdrawal latency (Figure 6A), while water fasting alone had no effect on baseline 
latency (Figure 6A). By presenting water instead of sucrose to sucrose-trained rats we 




































































water drinking alone was sufficient to increase withdrawal latency (Figure 6B). Animals 
trained to drink non-nutritive sucralose also displayed a significant increase in mean 
withdrawal latency from 8.5 ± 0.5 s to 12.3 ± 0.9 s (p=0.0026, paired t-test, t=4.112; 
n=10 rats) when presented with water instead of sucralose. A trial-to-trial comparison of 
drinking performance during the four repeat thermal stimulations per session revealed 
that the total time spent drinking water decreased progressively compared to sucrose 
over the same number of trials (Figure 6C), though was still sufficient to elicit analgesia 
equivalent to sucrose over the four trials tested (Two-Way repeat measures ANOVA: 
sucrose v water: F(1,66)=0.05, p=0.8317, n=12 rats). This suggested that the 
conditioning effect of sucrose driving water drinking in euvolaemic animals rapidly 
extinguishes after repeated water exposure. Systemic treatment with naloxone had no 
effect on the acute analgesia induced by sucrose-conditioned water drinking, 
suggesting it was not mediated by endogenous opioidergic mechanisms (Figure 6D).   
 
The opioid-independent nature of the analgesic response evoked by sucrose-
conditioned water drinking, and it’s rapid extinction are characteristic of non-opioid 
placebo analgesia [3, 22], which is thought to be mediated by cannabinoid CB1 
receptors [10]. We therefore investigated the potential role of endocannabinoid 
signalling using the well-characterised CB1 antagonist rimonabant (SR141716A).
Consistent with the role of CB1 receptors in controlling appetite [7, 24] systemic 
treatment with rimonabant at (5 mg/kg i.p.) in sucrose-trained rats led to a dramatic 
increase in the time taken to start drinking sucrose compared to vehicle (Figure 7A)




































































latency times were not significantly different from pre-training values (p=0.5550, 
unpaired t test; t=0.6088, n=7 rats). Therefore to bypass the suppressive effect of CB1 
antagonism on voluntary sucrose drinking we applied solutions directly to the oral cavity 
via an intraoral catheter [34, 38]. Administration of 20 µl sucrose solution intraorally 
elicited tongue and mouth movements in the animals without spillage indicative of 
tasting and active ingestion [34]. However, passive administration of sucrose solution in 
naïve animals was not sufficient to elicit thermal analgesia in rats compared with water 
perfusion or ‘sham’ dry running of the peristaltic pump as controls (Figure 7B), 
consistent with the reported loss of passive sucrose analgesia in development (>3 
weeks old rats) [5].  
 
This raised the question of whether the analgesic effect of oral sucrose requires prior 
experience of sucrose drinking. To address this question rats had chronic intraoral 
cannulation after sucrose drinking training. In the first session after recovery from 
cannulation we again saw no effect of oral sucrose perfusion compared to water or 
sham (air only) (Figure 7C). Interestingly, with repeated exposure via the oral cannula 
rats continued to consume sucrose (Movie 1) but in contrast allowed water to drip from 
their mouth (Movie 2), suggesting that a preference for sucrose had developed and that 
as a consequence water consumption was being avoided in these animals. By the fifth
repeat session of oral perfusion we observed a significant increase in withdrawal 
latency during sucrose perfusion (Figure 7D). In these animals, withdrawal latencies 
were consistently elevated during sucrose perfusion compared to water (Figure 7E). 




































































blocked the analgesic effect of sucrose (Figure 7F). Together, these results suggested 
that taste experience alone is not sufficient to reveal the analgesic effect of sucrose
drinking. Instead, the development of a preference for sucrose after repeated exposure 












































































We found that sucrose drinking in trained adult rats produces a robust and reproducible 
thermal analgesia which was sufficiently potent to oppose inflammatory thermal 
hyperalgesia. The magnitude of the analgesic effect was similar to that previously seen 
in neonates [61] and was seen in female as well as male animals. The analgesic effect 
was reproducible on repeated testing over hours and days and was temporally aligned 
to the periods of drinking behavior, consistent with previous reports of ingestive 
analgesia [29]. The effect extended to sucralose and to water (if fluid deprived or when 
consumption was conditioned by previous sucrose experience) indicating the analgesia 
was seen with hedonic drinking rather than simply nutritive or hydrative consumption 
[31].  
 
The main central projection of the gustatory nerves is to the nucleus of the solitary tract 
(NTS) [35], which in turn sends projections to the parabrachial (PB) nucleus [21]. 
Indeed, Fos-like immuno-reactivity is induced in the NTS and PB by analgesic sucrose 
consumption [6]. Direct electrical stimulation of the NTS produces analgesia in rats [52] 
and this has been linked to the release of beta-endorphin within the brainstem to 
produce an opioidergic analgesia [19]. The NTS and PB also make extensive 
connections to the key trimverate of this descending system namely the periaqueductal 
gray (PAG), locus coeruleus (LC) and the rostro-ventral medulla (RMV) [58]. We 
therefore reasoned that targeting the opioidergic neurotransmitter system may modulate 
the analgesic effect of sucrose.  However, treatment with naloxone (either spinally or 




































































sucrose drinking. Additionally, pre-treatment with D2-like receptor and α2-adrenergic 
receptors antagonist at doses sufficient to block spinal analgesia by dopaminergic [9] 
and noradrenergic agonists [39] also had no effect on the analgesic response of 
sucrose drinking.  Furthermore, the number of Fos-like nuclei in either the superficial or 
deep lamina of the spinal cord were not different between sucrose-fed and control 
groups, suggesting that sucrose analgesia is achieved without affecting either the input 
of noxious stimuli to the spinal cord [1] or interneuron circuits that drive the spinal 
reflexes [44]. Together these data suggest that the neonatal phenomenon [5, 15, 61] 
and the adult behavioral paradigm reported here are engaging distinct neural circuitry. 
 
A form of naloxone-sensitive sucrose analgesia has been reported in adult rats using 
the tail flick assay [23]. In our study we used the Hargreaves’ model of thermal 
nociception. Unlike the tail flick response, which is preserved in spinalized rats [41] the 
behavioral response to thermal stimulation of the hind paw (hot plate; Hargreaves) is 
thought to engage supra-spinal processing [20]. The latency of both the tail flick (a 
spinal reflex) and hot plate response are increased by stimulation of the PAG and RVM 
[42]. However, while the analgesic effect of RVM stimulation on the tail flick response 
can be inhibited by spinal administration of either opioidergic or monoaminergic 
antagonists, none of these treatments applied spinally antagonised the effect of RVM 
stimulation on the hot plate response [42] suggesting that such brainstem nuclei are 







































































Water is a strong motivator in water-deprived rats [63]. In our study water consumption 
by hypovolaemic rats also increased paw withdrawal latencies. Like sucrose in satiated 
rats, this observation is consistent with the potential role of reward pathways in the 
analgesic effect. Euvolaemic rats, as expected, were not motivated to drink water. 
However, by presenting water to rats after voluntary sucrose or sucralose training, we 
were not only able to motivate euvolaemic animals to drink water, but also to mimic the 
analgesic effect of both substances, suggesting that caloric consumption is not required 
and that brain pathways related to the expectation of gustatory reward [71] are sufficient 
for the analgesic effect.  
 
The effect of water consumption when presented to an animal expecting sugar reward 
is consistent with the definition of placebo analgesia [74]. In our study, the analgesic 
response evoked by sucrose-conditioned water drinking was not blocked by naloxone 
which suggested that this paradigm may be an example of non-opioid placebo 
analgesia [3]. Interestingly, over the course of the four trials we recorded progressively 
shorter drinking times for water than for sucrose in sucrose-trained animals, such that 
by the fifth trial rats did not drink water and therefore could not be tested further. This 
apparent extinction of the effect is again consistent with a placebo-like response [22]. 
 
The neuropharmacology of placebo responses are thought to differ depending on the 
context of the conditioning paradigm, with expectation-evoked placebo driven by 




































































transmitter systems [3]. In one of the original descriptions of sweet-substance analgesia 
by Dum & Herz it was shown that naloxone-sensitive analgesia could be elicited by 
expectation of sweet reward alone. [26]. In our paradigm we observed that simply 
expectation of reward in the absence of consumption was not sufficient to increase 
withdrawal latencies. This result could be due to the lack of a distinct conditioning cue, 
which in the case of a learned reward response is necessary to engage attentional 
circuits in the brain stem [17].  The opioid-dependency of sucrose analgesia may 
therefore depend on differences in the past learning experience of sucrose consumption 
[3]. 
 
The similarity with the characteristics of non-opioid placebo analgesia [3, 22] led us to 
investigate the possible contribution of cannabinoid CB1 receptors [10] to the sucrose 
analgesia phenomenon. Treatment with the CB1 receptor antagonist rimonabant 
significantly reduced the motivation of the animals to drink sucrose, consistent with the 
known suppressive effect of the drug on the consumption of palatable foods [7, 65].  
Therefore, in order to test the effect of the drug on withdrawal latencies during sucrose 
drinking we switched to a system of direct perfusion via an intraoral cannula. In contrast 
to previous studies in neonatal animals [5, 15, 61], passive intraoral administration of 
sucrose solution alone did not affect withdrawal latencies in naïve animals, nor when 
animals had previously been trained to voluntarily drink sucrose. Instead, the sucrose 
analgesia phenomenon was revealed by repeated exposure via the intraoral cannula
which resulted in a clear preference for sucrose compared to water perfusion. This 




































































development of a conscious preference for sucrose drinking in a specific context in 
order to endow the passively administered sucrose with sufficient hedonic value to elicit 
analgesia [31, 60].  
 
It is possible that the revelation of the analgesic phenomenon by repeated sucrose 
exposure also represents the diminishment of an aversive component over time, which 
may otherwise mask an innate reward-analgesia by sucrose [16]. Conversely, the 
extinction of conditioned voluntary water consumption, and the failure to ingest orally 
perfused water could represent the development of an aversion to the previously neutral 
water in parallel to the learned preference for sucrose. Given the positive association 
between the preference for sweet drinks and the frequency of their consumption [33] 
our findings have implications for strategies to reduce the consumption of sugar-
sweetened beverages, particularly in young children and adolescents [27]. 
 
We found that CB1 receptors play a critical role in the context of sucrose-conditioned 
analgesia. The neural pathway underlying this effect remains unknown but we may find 
clues in the role of endocannabinoids in food intake [24]. Feeding during satiety (a mark 
of hedonic consumption) has been linked to CB1 receptor signalling in both the 
hypothalamus [50] and PBN [25]. As a site of convergence of gustatory [21] and 
hypothalamic [2] pathways, and an important relay for spinal projection neurons [11], 
the PBN is well placed to modulate ascending nociceptive signalling by hedonic 
consumption. Interestingly, hypothalamic projections to the PBN have recently been 




































































endocannabinoid signalling in the hypothalamic-PBN pathway could be sufficient for 
sucrose analgesia; however, important questions remain as to how this pathway could 
be specifically activated after learned sucrose–conditioning. 
 
In humans, evidence of an analgesic-like response to oral sucrose is consistently 
observed in newborns [68, 72], while reports in adults are mixed [13, 46, 60]. The 
distinction between the supra-spinal analgesia we have observed here in the adult rat, 
and the descending spinal analgesia reported in neonatal animals [5, 15, 26], could help 
to explain some of the discrepancy. Intriguingly, the analgesic effect of oral glucose 
administration in newborns undergoing a minor procedure was not blocked by 
intravenous naloxone [32]. This raises the question of whether in fact the opioid-
independent, supra-spinal analgesia we have observed in adult rats has more in 
common with human newborns, which also lack observable spinal nociceptive 
modulation during sucrose analgesia [66]. The prospect of sucrose mediating a 
placebo-like phenomenon also raises important ethical questions for the use of sucrose 
as an analgesic in newborn infants [28]. Further knowledge of the neural circuits 
involved will help not only inform the use of sucrose as an analgesic on the pediatric 
wards [66, 68], but also the neurological drivers of hedonic overconsumption leading to 
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Figure 1.  
Active consumption of sucrose (10%) solution in fasted rats increases hind paw 
withdrawal latency to heat. (A) Reward drinking and hind paw thermal sensory testing 
apparatus. (B) Naïve rats were food deprived overnight (16h) before being offered a 
sucrose (10%) solution through a window in the testing chamber. (C) Thermal sensitivity 
was tested at rest before and after fasting, and re-tested on commencement of drinking 
with sucrose solution. Heat stimulus was applied to the right hind paw four times (during 
separate trials) and the average latency plotted.  Bars represent mean ± SEM. Repeat 
measures one-way ANOVA F(2,15)=26.00, n=6, p=0.0001; Bonferroni post-test, 
***p<0.001. ns, not significant. 
 
Figure 2.  
Training reveals analgesic effect during active sucrose drinking in non-fasted rats. (A) 
Time to drink reward from window opening. Rats were trained in daily sessions to drink 
10% sucrose solution provided through window (30s access periods, 4 repeat trials per 
session, 6-8 session repeats). Session 3, not determined. Bars represent mean ± SEM.  
One way repeat measures ANOVA, F(4,44)=7.571 with Dunnett’s multiple comparisons 
to session 1,  **p<0.01, ***p<0.001. (B) Non-fasted, sucrose trained rats. Withdrawal 
latency at rest and during sucrose drinking. n=12 rats, Paired Student’s t-test. (C) 
Thermal withdrawal latency at rest and during access to the solution reservoir in the 




































































sucralose (0.017% w/v). Withdrawal latency at rest and during sucralose drinking. n=12 




Sucrose drinking attenuates thermal hypersensitivity after local inflammation. The 
analgesic effect of sucrose drinking on heat withdrawal latencies on both paws was 
checked on all animals in a pre-test session (Day 0) and again on Day 2. On Day 1 all 
rats received an intraplantar injection of complete Freund’s adjuvant (CFA, 50 µg, 2:1 
emulsion in sterile saline, arrow) in one paw (ipsilateral). (A) Thermal sensitivity in CFA 
inflamed (ipsiateral) hind paw. Absolute withdrawal latencies over time (left). Repeat 
measures One-way ANOVA: F(3,27)=111.3, p<0.0001 with Bonferroni post-test, 
*p<0.05, ***p<0.001 (n=10 rats). Percentage change in latency (right). Paired t-test, 
p=0.6846. (B) Thermal sensitivity in untreated (contralateral) hind paw. Absolute 
withdrawal latencies over time (left). Repeat measures One-way ANOVA: 
F(3,27)=44.46, p<0.0001 with Bonferroni post-test, ***p<0.001 (n=10 rats). ns, not 
significant. Percentage change in latency (right). Paired t-test, p=0.0554.  
 
Figure 4. 
Sucrose drinking analgesia is not prevented by systemic or spinal naloxone, systemic 
dopamine D2-like receptor or spinal alpha2-adrenergic receptor blockade. (A) 8-10 
week male SD rats treated with naloxone (1 mg/kg) or vehicle (saline) i.p. 10 min before 




































































Effect of sucrose F(1,10)=39.63, p<0.0001; Bonferonni post-test, *p<0.05, ***p<0.001. 
(B) Spinal treatment with naloxone (10 µg) or vehicle (saline) i.t. 10 min before thermal 
latency testing. Two way ANOVA: Effect of naloxone F(1,9)=0.54 p=0.4799. Effect of 
sucrose F(1,10)=98.74, p<0.0001; Bonferonni post-test, ***p<0.001. (C) 8-10 week male 
SD rats treated with sulpiride (10 mg/kg) or vehicle (10% DMSO in saline) i.p. 10 min 
before thermal latency testing. Two way ANOVA: Effect of sulpiride F(1,10)=0.05 
p=0.8215. Effect of sucrose F(1,10)=22.15, p=0.0008; Bonferonni post-test, *p<0.05, 
**p<0.001. (D) Spinal treatment with yohimbine (30 µg) or vehicle (30% DMSO in 
saline) i.t. 10 min before thermal latency testing. Two way ANOVA: Effect of yohimbine 
F(1,11)=1.91 p=0.1948. Effect of sucrose F(1,11)=20.19, p=0.0009; Bonferonni post-
test, *p<0.05, **p<0.01. 
 
Figure 5. 
Sucrose consumption does not affect expression of spinal c-fos during thermal 
stimulation of the hind paw. (A) c-fos-like immunoreactivity in the ipsilateral dorsal horn 
of the lumbar L4-6 spinal cord in control (above) and sucrose fed (below) male rats after 
repeated hind paw thermal stimulation. Note dark stained nuclei in the dorso-medial 
region of the superficial lamina (outlined by white dashed line) and neck region of the 
deep lamina. (B) Quantification of c-fos-like nuclei in control and sucrose-fed groups.  
Two-way ANOVA. Effect of sucrose: F(1,16)=0.01, p=0.9084; n=4 sections per rat, 5 






































































Water drinking by water-deprived or sucrose-expectant rats increases paw withdrawal 
latency to heat. (A) Naïve rats were Hargreaves’ tested before and after water 
deprivation (24h) at rest, and again at the commencement of drinking sucrose (10%) 
solution. Repeat measures one way ANOVA: F(2, 15)=49.48, p<0.0001. Bonferroni 
post-test: ***p<0.001. (B) Unlike naïve animals, previously sucrose-trained rats drank 
water, increasing withdrawal latency.  Paired Student’s t -test. (C) Total licking time 
declines during water drinking in sucrose-conditioned rats compared to sucrose 
drinking. Two-way ANOVA: Sucrose versus water drinking, F(1,30)=15.38, p=0.0029; 
Bonferonni post-test, *p<0.05, **p<0.01. (D) Systemic naloxone (1 mg/kg) did not 
prevent the analgesic effect of conditioned water drinking. Two-way ANOVA: Effect of 
naloxone, F(1,10)=2.79, p=0.1257; Effect of water, F(1,10)=39.86, p=0.0002; 
Bonferonni post-test, *p<0.05, **p<0.01. 
 
Figure 7. 
Sucrose analgesia in trained rats is depedent on endogenous activation of cannabinoid 
CB1 receptors. (A) CB1 receptor antagonist SR141716A (5 mg/kg, i.p.) increased the 
latency to start drinking sucrose.  Sucrose trained animals were divided randomly into 
two groups. Each group received either the antagonist or vehicle and received the 
alternate injection two days later (p=0.0004, paired t test, t=6.951; n=7 rats). (B) 
Passive consumption of sucrose in naïve rats has no effect on thermal nociception. 
Naïve rats had an intra-oral catheter implanted under anaesthesia and then recovered 




































































perfusion of water, sucrose (10%) or air (sham) at 2 µl/s. Bars represent mean ± SEM. 
Repeat measures one-way ANOVA, F(2, 17)=0.7544, p=0.4953; n=6 rats, with 
Bonferroni post-test for multiple comparisons. ns, not significant. (C) Sucrose-trained, 
chronically cannulated rats provided sucrose or water via intraoral cannula for the first 
time. Thermal withdrawal latencies were tested during oral perfusion of water, sucrose 
(10%) or air (sham) at 15 µl/s. p=0.1494, repeat measures one-way ANOVA F(2
23)=2.184, n=8 rats, with Bonferroni post-test for multiple comparisons, ns, not 
significant. (D) Sucrose-trained, chronically cannulated rats provided sucrose or water 
via intraoral cannula after five repeat sessions. Thermal paw withdrawal latencies were 
significantly increased during oral perfusion of sucrose (10%) compared to water or air 
(sham) at 15 µl/s. p=0.001, repeat measures one-way ANOVA F(2, 23)=18.04, n=8 rats,
with Bonferroni post-test for multiple comparisons, **p<0.01 (t=4.304), ***p<0.001 
(t=5.781). (E, F) Effect of CB1 receptor antagonist rimonabant or vehicle treatment on 
thermal paw withdrawal latencies during perfusion of water or sucrose in cannula 
experienced rats. (E) Withdrawal latencies were significantly increased during sucrose 
perfusion compared to water in vehicle-treated animals (p=0.0066, paired t-test, t=3.813;
n=8 rats). (F) Rimonabant (5 mg/kg, i.p.) given 15 min prior to testing prevented the 







































































Intra-oral perfusion of sucrose (10% in water; 15 µl/s) in chronically cannulated rat after 
5 repeat perfusion sessions. Note the movements of the tongue and mouth in the 
without spillage.  
 
Movie 2.  
Intra-oral perfusion of water only (15 µl/s) in chronically cannulated rat after 5 repeat 
perfusion sessions. Note the spillage of the water from the mouth in the absence of 





































































Summary (25 words max) 
 
Scientific: 
Hedonic drinking induces a potent thermal analgesia mediated supra-spinally by 
endocannabinoid signalling at CB1 receptors. 
 
Lay: 
Drinking sweet beverages suppresses the behavioural response to heat pain due to the 
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Figure 1
Sucrose training
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